NCT04150094

Brief Summary

This is a randomized blinded trial with non-probabilistic sampling for convenience. Our goal is to compare PFMT with intravaginal vibratory stimulus versus PFMT alone on the treatment of female urinary incontinence.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 10, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 31, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 4, 2019

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2021

Completed
Last Updated

September 22, 2023

Status Verified

September 1, 2023

Enrollment Period

2.4 years

First QC Date

October 31, 2019

Last Update Submit

September 21, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in urinary incontinence

    We will measure it using the "International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) - Portuguese version", pre and post treatment, to assess if there are any changes in bladder control after the protocols. It consists of 3 scored items which evaluate the frequency, volume of leakage and overall impact of incontinence. The overall score ranges from 0 to 21, with greater values indicating increased severity. Klovning et al (2009) says that ICIQ-SF may be divided into the following four severity categories of UI: slight (1-5), moderate (6-12), severe (13-18) and very severe (19-21). Lim et al (2019) suggested that for women undergoing nonsurgical treatments for incontinence, reductions of 4 points in ICIQ-UI SF are perceived as clinically meaningful.

    8 weeks

Secondary Outcomes (1)

  • Impact in quality of life

    8 weeks

Study Arms (2)

Pelvic floor muscle training (PFMT)

ACTIVE COMPARATOR

Pelvic floor muscle training without stimulus.

Other: Pelvic floor muscle training (PFMT)

Pelvic floor muscle training + intravaginal vibratory stimulus

EXPERIMENTAL

Pelvic floor muscle training with intravaginal vibratory stimulation.

Other: Pelvic floor muscle training + intravaginal vibratory stimulus

Interventions

Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.

Pelvic floor muscle training (PFMT)

Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.

Pelvic floor muscle training + intravaginal vibratory stimulus

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women with urinary incontinence;
  • Know how to perform a voluntary pelvic floor muscle contraction;
  • Have not undergone pelvic floor muscle training in the last 6 months;
  • Understand the instruments used in research.

You may not qualify if:

  • Latex allergy;
  • Neurological diseases;
  • Pelvic organ prolapse \> grade 2;
  • Pain during vaginal palpation and / or introduction of the vaginal probe;
  • Vaginal atrophy;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

José Geraldo Lopes Ramos

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

Location

MeSH Terms

Conditions

Urinary Incontinence

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Jose Geraldo Lopes Ramos

    Hospital de Clinicas de Porto Alegre

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2019

First Posted

November 4, 2019

Study Start

July 10, 2019

Primary Completion

December 20, 2021

Study Completion

December 20, 2021

Last Updated

September 22, 2023

Record last verified: 2023-09

Locations